Ibrutinib is more effective than standard therapy for treating elderly patients with chronic lymphocytic leukaemia (CLL), according to new research.
The study, published in the New England Journal of Medicine in December, compared single-agent ibr...
5 years ago
Venetoclax, a novel drug for chronic lymphocytic leukaemia (CLL), has been fast-tracked by the National Institute for Health & Care Excellence (NICE) into NHS use, it was announced last week.
After reaching a deal with the drug’s manufacturer,...
5 years ago
